VivoSim Labs, Inc. (VIVS) AI Stock Analysis

VivoSim Labs, Inc., formerly known as Organovo Holdings, Inc., is a pharmaceutical and biotechnology services company headquartered in San Diego, California. The company provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. Through its new approach methodologies (NAM) models, it offers partners liver and intestinal toxicology insights and predictive screening services. Additionally, VivoSim Labs studies intestinal side effect profiles for therapeutics and builds functional 3D human tissues using proprietary technologies, high throughput systems, bioprinted systems, and flow/stretch capable platforms to mimic native tissue architecture, function, and disease.

Revenue declined from $1.5M in FY2022 to $370,000 in FY2023 and $109,000 in FY2024, before increasing 32.1% to $144,000 in FY2025. In FY2026, revenue fell 9.0% to $131,000, contributing to a 5-year revenue CAGR of -43.1% from FY2020 to FY2026. Gross margin was 100.0% in FY2022, FY2023, FY2024, and FY2026, and 96.5% in FY2025. Operating margins remained deeply negative, reaching -8567.9% in FY2026 alongside net income of -$13.8M and diluted EPS of -$5.36. R&D expense stood at $4.2M in FY2026. In the latest quarter ending June 30, 2026, quarterly revenue growth fell 51.4% year-over-year, leaving trailing twelve month revenue at $112,000 and EPS at -$4.47.

As of June 30, 2026, VivoSim Labs held $1.7M in cash and short-term investments against total debt of $316,000, yielding net cash of $1.4M. Total assets stood at $3.8M, and the current ratio was 1.70. However, shareholders' equity was -$2.3M. Operating cash flow was -$10.8M and free cash flow was -$10.8M in FY2026. The company does not conduct share buybacks or pay dividends, and its 5-year share count change reached 622.2%.

VivoSim Labs holds a market cap of $2.6M and an enterprise value of $1.7M. The stock trades at a price-to-sales multiple of 23.2x and an enterprise value to revenue ratio of 15.4x, compared to the median price-to-sales ratio of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 0.5x. Shares closed at $0.16 on October 16, 2026, trading 86.3% below their 200-day average. Over the past year, the stock fell 93.9%, compared to a 16.8% return for the S&P 500 (SPY), while its 5-year return of -99.8% lagged the index return of 83.0%.

Wall Street analysts project a revenue estimate of $0 for the current fiscal year ending March 31, 2027. No price targets or recommendation counts are provided. VivoSim Labs achieved 4 EPS beats over the last 4 quarters, recording a trailing twelve month EPS of -$4.47. The company is scheduled to report its next earnings on November 5, 2026.

This page is an AI-written research summary of VivoSim Labs, Inc. (VIVS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VIVS income statement, VIVS balance sheet, VIVS key metrics, VIVS analyst forecast, VIVS chart. See the VIVS stock overview for the latest quote and news.